Skip to Content
Merck
All Photos(1)

Key Documents

20050-U

Supelco

ORBO 608 Amberlite XAD®-2 (20/50) 150/75 mg

W,W,W separators, O.D. × L 8 mm × 110 mm, pkg of 50 ea

Synonym(s):

ORBO Amberlite XAD-2 Tube

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12190000
NACRES:
NB.24
Pricing and availability is not currently available.

material

W,W,W separators

Agency

NIOSH 2514,2543,5514

product line

Amberlite
ORBO

composition

Bed A, 150 mg
Bed B, 75 mg

packaging

pkg of 50 ea

manufacturer/tradename

ORBO 608

technique(s)

active air sampling: suitable

O.D. × L

8 mm × 110 mm

matrix

XAD-2

particle size

20-50 mesh

application(s)

air monitoring
environmental
industrial hygiene

Looking for similar products? Visit Product Comparison Guide

General description

ORBO sorbent tubes (W,W,W separators, O.D. × L 8 mm × 110 mm) contain two beds of the same selective adsorbent separated by glass wool or foam, for gas and vapor sampling. The dual-layer or two-bed construction of the tube allows for any sample breakthrough to be captured in the smaller back-up bed.

Legal Information

Amberlite is a trademark of DuPont de Nemours, Inc.
ORBO is a trademark of Sigma-Aldrich Co. LLC
XAD is a registered trademark of The Dow Chemical Company or an affiliated company of Dow

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A Orbo et al.
International journal of oncology, 5(3), 619-625 (1994-09-01)
About 50% of the cases with invasive carcinoma of the uterine cervix occurs before menopause. Cyclic changes of sex steroids may therefore interfere with the ratio between extracellular levels of cGMP and cAMP (cGMP(ex)/cAMP(ex)). This ratio has been proposed as
H Stalsberg et al.
Virchows Archiv. A, Pathological anatomy and histopathology, 414(5), 415-422 (1989-01-01)
The autopsies of 12 victims from two snow avalanches in North-Norway are reported. Supportive evidence from non-autopsied and surviving victims is included. Consistent autopsy findings were prominent lung oedema, moderate cerebral oedema, extreme contraction of the left ventricle, petechiae in
A Orbo et al.
Gynecologic oncology, 95(1), 82-88 (2004-09-24)
The purpose of the current study was to characterize the role of PTEN in malignant transformation and to evaluate the significance of mutated PTEN exons as prognostic markers in the carcinogenesis of endometrial hyperplasia. A comparison of PTEN mutations as
A Ørbo et al.
BJOG : an international journal of obstetrics and gynaecology, 123(9), 1512-1519 (2015-12-03)
To investigate relapse rates after the successful treatment of patients with non-atypical endometrial hyperplasia who were randomised to either a levonorgestrel-impregnated intrauterine system (LNG-IUS; Mirena(®) ) or two regimens of oral medroxyprogesterone acetate (MPA) after primary histological response. A multicentre
Anne Beate Vereide et al.
Gynecologic oncology, 97(3), 740-750 (2005-05-12)
The aim of the study was to investigate apoptosis as a growth regulatory mechanism of gestagen in endometrial precancers and to compare differences in the apoptotic cascade after high and low dose gestagen regimens. Pre- and post-treatment paraffin-embedded endometrial hyperplasia

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service